REFERENCES

1. Mahdi QA, Ahmed BS, Kadhim MA. The frequency of thyroid carcinoma in patients with solitary and multiple nodules utilizing ultrasound guided fine needle aspiration cytology (FNAC): A prospective study (Thyroid carcinoma and U/S guided FNA). Journal of the Faculty of Medicine. 2010;52(2):136-40.
2. Gandolfi PP, Frisina A, Raffa M. The incidence of thyroid carcinoma in multinodular goiter: retrospective analysis. Acta Bio Medica Atenei Parmensis. 2004 Aug 1;75(2):114-7.
3. Brahimi-Horn MC, Chiche J, Pouysségur J. Hypoxia and cancer. Journal of molecular medicine. 2007 Dec 1;85(12):1301-7.
4. Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Molecular pharmacology. 2006 Nov 1;70(5):1469-80.
5. Vooijs MA, Gort EH, Groot AJ, der Wall EV, van Diest PJ. Hypoxic regulation of metastasis via hypoxia-inducible factors. Current molecular medicine. 2008 Feb 1;8(1):60-7.
6. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell death and differentiation. 2008 Apr;15(4):678.
7. Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Molecular cell. 2010 Oct 22;40(2):294-309.
8. Luna LG. Manual of histologic staining methods of the Armed Forces Institute of Pathology. Armed Forces Institute of Pathology (US). Armed Forces Institute of Pathology (US).; 1968.
9. Munro BH. Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology. Pathology. 1971 Jan 1;3(3):249.
10. Centre for Evidence-Based Medicine (CEBM, University of Oxford). OCEBM Levels of Evidence. https://www.cebm.net/2016/05/ocebm-levels-of-evidence/ (accessed 17 July 2018).
11. Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, Niu Y, Du L. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta‐analysis, and clinical practice guideline: a systematic review. Journal of evidence-based medicine. 2015 Feb;8(1):2-10.
12. Greenhalgh T, Howick J, Maskrey N. Evidence based medicine: a movement in crisis?. Bmj. 2014 Jun 13;348:g3725.
13. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell death and differentiation. 2008 Apr;15(4):678.
14. Jóźwiak P, Ciesielski P, Zaczek A, Lipińska A, Pomorski L, Wieczorek M, Bryś M, Forma E, Krześlak A. Expression of hypoxia inducible factor 1α and 2α and its association with vitamin C level in thyroid lesions. Journal of biomedical science. 2017 Dec;24(1):83.
15. Smith TG, Robbins PA, Ratcliffe PJ. The human side of hypoxia‐inducible factor. British journal of haematology. 2008 May;141(3):325-34.
16. Eales KL, Hollinshead KE, Tennant DA. Hypoxia and metabolic adaptation of cancer cells. Oncogenesis. 2016 Jan;5(1):e190.
17. Loboda A, Jozkowicz A, Dulak J. HIF-1 versus HIF-2—is one more important than the other?. Vascular pharmacology. 2012 May 1;56(5-6):245-51.
18. Bersten DC, Sullivan AE, Peet DJ, Whitelaw ML. bHLH–PAS proteins in cancer. Nature Reviews Cancer. 2013 Dec;13(12):827.
19. Koh MY, Lemos R, Liu XP, Powis G. The hypoxia associated factor (HAF) switches cells from HIF-1α to HIF-2α dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer research. 2011 Apr 21:canres-4142.
20. Abd‑Aziz N, Stanbridge EJ, Shafee N. Bortezomib attenuates HIF-1-but not HIF-2-mediated transcriptional activation. Oncology letters. 2015 Oct 1;10(4):2192-6.
21. Påhlman S, Lund LR, Jögi A. Differential HIF-1α and HIF-2α expression in mammary epithelial cells during fat pad invasion, lactation, and involution. PLoS One. 2015 May 8;10(5):e0125771.
22. Mandel SJ. A 64-year-old woman with a thyroid nodule. Jama. 2004 Dec 1;292(21):2632-42.
23. Mahdi QA, Ahmed BS, Kadhim MA. The frequency of thyroid carcinoma in patients with solitary and multiple nodules utilizing ultrasound guided fine needle aspiration cytology (FNAC): A prospective study (Thyroid carcinoma and U/S guided FNA). Journal of the Faculty of Medicine. 2010;52(2):136-40.
24. Castro MR, Gharib H. Continuing controversies in the management of thyroid nodules. Annals of internal medicine. 2005 Jun 7;142(11):926-31.
25. Al-Rrawak K, Al-Sarraf SA, Sulaiman TI. Changing Patterns of Thyroid Pathology and Trends of Surgical Treatment. Journal of the Faculty of Medicine. 2009;51(1):12-6.
26. Liu R, Xing M. TERT promoter mutations in thyroid cancer. Endocrine-related cancer. 2016 Jan 5:ERC-15.
27. Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxia-inducible factors 1α and 2α on mTORC1 and mTORC2. Journal of Biological Chemistry. 2008 Dec 12;283(50):34495-9.
28. Burrows N, Resch J, Cowen RL, et al. Expression of hypoxia-inducible factor 1α in thyroid carcinomas. Endocrine-Related Cancer. 2010;17(1):61-72. doi:10.1677/ERC-08-0251.